Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Systems and methods for multivariate analysis of adverse event data

a multi-variate analysis and data technology, applied in the field of systems, can solve the problems of inability to examine other factors, inability to analyze other factors, and inability to analyze other factors, and achieve the effects of avoiding the use of drugs

Inactive Publication Date: 2015-04-16
MOLECULAR HEALTH GMBH
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a system that can analyze biomolecules and determine their interactions with each other. This information can be used to create personalized medicine that targets specific proteins or pathways in the body. The system can also identify which biomolecules are causing adverse reactions and suggest alternative treatments to reduce these reactions. Overall, this technology can help create safer and more effective drugs for patients.

Problems solved by technology

However, analysis of such data is typically limited to simple univariate analysis, such as rates of adverse events associated with a medication.
Such analysis may fail to examine other factors and associations between medications or relationships between molecular entities associated with the medications, such as target (and off-target) proteins, enzymes, transporters, pathways, drug classes, or other information.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Systems and methods for multivariate analysis of adverse event data
  • Systems and methods for multivariate analysis of adverse event data
  • Systems and methods for multivariate analysis of adverse event data

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0134]Adverse events are a common and, for the most part, unavoidable consequence of therapeutic intervention. The identification of novel adverse events is critical to the protection of patient well-being and the healthcare system that supports them. From the induction of avoidable and sometimes fatal side effects to the billions of dollars in associated medical costs, adverse events (AE's) remain a critical issue for all stakeholders in the healthcare system.

[0135]Data about adverse events are provided by clinicians, researchers, and manufacturers to spontaneous reporting systems, such as the U.S. Food and Drug Administration's Adverse Event Reporting System (AERS). After a manual review of each submission the data are made publically available on quarterly basis via the online AERS data files. All reports contain information surrounding the treatment, side effects, and patient characteristics / demographics. Drug information is further qualified as to whether the drug is suspected ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure describes systems and methods for multivarlate analysis of adverse event data. According to a first aspect, patient-specific genomic Information is used to optimize or de-risk therapy for the patient. According to other aspects of the invention, unknown drug targets are identified via adverse event data. According to still other espects, a medication is identified to exclude from use for an indication or from a clinical trial of another medication. According to another aspect, a predicted side effect profile is generated for a medication targeting a novel target. According to still another aspect, combination therapies are identified via adverse event data. According to another aspect, molecular interactions between a plurality of molecular entities are displayed in an intuitive format. According to still another aspect, molecular entities responsible for adverse event differences between similar indications are identified. According to still another aspect, genetic variants associated with adverse events in a clinical trial are identified.

Description

RELATED APPLICATIONS[0001]The present application claims priority to and the benefit of U.S. Provisional Patent Application No. 61 / 584,164, entitled “Translating Clinico-Molecular Data Into Safer, More Effective Drug Choices”, filed Jan. 6, 2012; U.S. Provisional Patent Application No. 61 / 605,625, entitled “Systems and Methods for Analysis of Adverse Event Data”, filed Mar. 1, 2012; U.S. patent application Ser. No. 13 / 446,917, entitled “Systems and Methods for Personalized De-Risking Based on Patient Genome Data”, filed Apr. 13, 2012; U.S. patent application Ser. No. 13 / 446,871, entitled “Systems and Methods for Identifying Unknown Drug Targets via Adverse Event Data”, filed Apr. 13, 2012; U.S. patent application Ser. No. 13 / 446,820, entitled “Systems and Methods for De-Risking Clinical Trials”, filed Apr. 13, 2012; and U.S. patent application Ser. No. 13 / 446,912, entitled “Systems and Methods for Using Adverse Event Data to Predict Potential Side Effects”, filed Apr. 13, 2012; each...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G06F19/00G06F19/18G16B20/20G16H10/60G16H20/10G16H70/40
CPCG06F19/345G06F19/18G06F19/3437G06F19/326G16H50/50G16H50/20G16B20/00G16H20/10G16H70/40G16B20/20
Inventor JACKSON, DAVIDSOLDATOS, THEODOROSTAGLANG, GUILLAUMEZIEN, ALEXANDERBROCK, STEPHAN
Owner MOLECULAR HEALTH GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products